News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Genetix Group plc (GTX.L)'s CytoVision(R) with GSL-120 Streamlines Cytogenetic Analysis Across the Globe

11/18/2009 1:50:34 PM

New Milton, Hampshire, UK, 18 November 2009 – Genetix, a leading provider of solutions for imaging and image analysis, announces that it is achieving global acceptance for its GSL-120 automatic slide loader system. The system is now installed and running in hospital and research laboratories in North America, Middle East, Asia Pacific, Europe, and most recently has been purchased by a major commercial clinical laboratory in Japan. Introduced 18 months ago, the GSL-120 is used under the control of the Company’s CytoVision® software platform to enable unattended scanning and image capture of samples submitted for cytogenetic analysis.

Capable of processing up to 120 slides per batch, while feeding images directly to review stations for on-screen analysis by cytogeneticists, the unique combination of GSL-120 and CytoVision has significantly enhanced efficiency and productivity wherever installed. Laboratories are reporting shortened turnaround times and reduced backlogs of patient samples. The installations are used for a variety of applications, predominantly karyotyping, but also other brightfield and fluorescence-based applications.

In Australia, Sydney Genetics, a private cytogenetics laboratory in New South Wales and asubsidiary of Sydney IVF, acknowledged that: “The reduction in analysis time and increased case workload is mainly a result of less time spent manually searching for suitable cells for analysis and capture.”

The National Health Service Scotland, one of the European installations that uses the CytoVision platform, provides a national service. Eddy Maher, Director of Cytogenetic Services, NHS Lothian, said: “The ability to automate brightfield G- and R- band karyotyping is enabling our laboratory to carry out routine genetic abnormality screening more efficiently, freeing up time for scientists to research novel techniques and assays and so enhance our services going forward.”

At the University of Turkey, Professor Seher Basaharan, a leader in the filed of pre-natal screening to identify potential chromosomal abnormalities, confirmed: “CytoVision with GSL-120 is a vital addition to our facility, enabling us to provide results to clinicians sooner and cope with the increased need for cytogenetic screening.”

Charles de Rohan, CEO, Genetix, commented: “The CytoVision platform is now used in almost 2000 facilities. The rapid adoption of the GSL-120 system across all continents clearly demonstrates that we are fulfilling the needs of today’s busy cytogenetics laboratories.”

About Genetix (

Headquartered in New Milton, UK, with offices in the UK, US, Germany and Japan, and quoted on the AIM (GTX: AIM), Genetix provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis in the life science and diagnostic markets.

In research, pharmaceutical and biotherapeutic development, the Company’s systems set industry standards for screening and selection of mammalian secretory cell lines. Other systems evaluate the response of cells to potential therapeutic agents and quantify tissue biomarkers.

In diagnostics, Genetix holds a leading position in genetic testing with thousands of the Company’s platforms used in laboratories worldwide.

Through its expertise in robotics, cell and molecular biology, image analysis and interpretation, supported by a strong IP portfolio, Genetix is committed to the continual development of innovative solutions.

Read at

comments powered by Disqus